Cardiometabolic adverse effects of long-term antipsychotic treatment in children and adolescents with non-psychotic disorders: a systematic review of available evidence.
Saved in:
| Title: | Cardiometabolic adverse effects of long-term antipsychotic treatment in children and adolescents with non-psychotic disorders: a systematic review of available evidence. |
|---|---|
| Authors: | Radha Krishnan, Ramya Padmavathy (AUTHOR), Dzidowska, Monika (AUTHOR), Zheng, Danni (AUTHOR), Wong, Zoie Shui-Yee (AUTHOR), Buckley, Nicholas A. (AUTHOR), Raubenheimer, Jacques Eugene (AUTHOR) |
| Source: | European Child & Adolescent Psychiatry. Nov2025, Vol. 34 Issue 11, p3331-3343. 13p. |
| Subjects: | Drug therapy for psychoses, Risk assessment, Medical information storage & retrieval systems, Hyperlipidemia, Myocardial ischemia, CINAHL database, Hypertension, Long-term health care, Antipsychotic agents, Cardiovascular diseases risk factors, Risperidone, Descriptive statistics, Systematic reviews, MEDLINE, Hyperglycemia, Metabolic syndrome, Psychology information storage & retrieval systems, Weight gain, Thrombosis, Adolescence, Children |
| Abstract: | Antipsychotics are known to cause cardiovascular and metabolic adverse effects, but there is less evidence for their use off-label, especially in children and adolescents. Such treatments may be administered over long durations. We conducted a systematic review to examine the cardiometabolic adverse effects of prolonged antipsychotic treatment in children and adolescents with non-psychotic disorders. We searched for randomised clinical trials and observational studies lasting for a year or more, examining the adverse outcomes of weight gain, hyperglycaemia, dyslipidaemia, hypertension, metabolic syndrome, ischaemic heart disease, and thrombosis. There were no randomised trials, and 15 observational studies involved 114,141 participants with mean age of 10.9 years (range of means 4.3–14.9 years). Twelve antipsychotics were covered but the majority (12 studies, 80%) examined risperidone. Using the vote counting method, long-term antipsychotic treatment was associated with weight gain (91.6% studies, n = 12), hyperglycaemia (100%, n = 6), dyslipidaemia (66.6%, n = 6), and metabolic syndrome (100%, n = 2). Hypertension was demonstrated in only one study (25%, n = 4), and none examined ischaemic heart disease or thrombosis. Studies exhibited moderate to high methodological quality. Prolonged exposure to antipsychotics during childhood may be associated with several metabolic adverse effects that could have long-term health impacts. Longer-term studies on a wider range of agents are required to clarify risks and develop appropriate strategies to mitigate them. Antipsychotic prescribing for children should be assessed on an individual basis, after weighing the benefits of therapy against the harms that may arise. Children need to be monitored for these metabolic effects, and early intervention is essential if adverse effects are severe. [ABSTRACT FROM AUTHOR] |
| Copyright of European Child & Adolescent Psychiatry is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
